Evidence map›Paper›PMID 34671770›Full record

ArticlebioRxiv : the preprint server for biology2021

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.

Young-Jun Park, Anna De Marco, Tyler N Starr, Zhuoming Liu, Dora Pinto, Alexandra C Walls, Fabrizia Zatta, Samantha K Zepeda, John Bowen, Kaitlin S Sprouse and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Anna De MarcoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Tyler N StarrBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Dora PintoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Fabrizia ZattaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Samantha K ZepedaDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
John BowenDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Kaitlin S SprouseDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Anshu JoshiDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Martina GiurdanellaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Barbara GuarinoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Julia NoackVir Biotechnology, San Francisco, CA, USA.
Rana AbdelnabiRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Shi-Yan Caroline FooRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Florian A LemppVir Biotechnology, San Francisco, CA, USA.
Fabio BenigniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA.
Johan NeytsRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Sean Pj WhelanDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Herbert W VirginVir Biotechnology, San Francisco, CA, USA.
Jesse D BloomBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Matteo Samuele PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.

Funding

Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
NIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201700059C
6 · The paper itself

Abstract

Understanding broadly neutralizing sarbecovirus antibody responses is key to developing countermeasures effective against SARS-CoV-2 variants and future spillovers of other sarbecoviruses. Here we describe the isolation and characterization of a human monoclonal antibody, designated S2K146, broadly neutralizing viruses belonging to all three sarbecovirus clades known to utilize ACE2 as entry receptor and protecting therapeutically against SARS-CoV-2 beta challenge in hamsters. Structural and functional studies show that most of the S2K146 epitope residues are shared with the ACE2 binding site and that the antibody inhibits receptor attachment competitively. Viral passaging experiments underscore an unusually high barrier for emergence of escape mutants making it an ideal candidate for clinical development. These findings unveil a key site of vulnerability for the development of a next generation of vaccines eliciting broad sarbecovirus immunity.

Identifiers

PMID34671770
PMCPMC8528076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.